IN8bio's DeltEx Therapy Doubles Progression-Free Survival in Glioblastoma Trial — IN8bio, Inc.

Event summary

IN8bio's Phase 1 trial of DeltEx™ DRI in glioblastoma patients showed median progression-free survival (mPFS) of 16.1 months, more than double the ~6.9-month standard of care benchmark.
The study published in The Journal of Clinical Oncology involved 13 patients treated with repeat doses of DeltEx™ DRI, demonstrating no dose-limiting toxicities or immune-mediated side effects.
Repeat-dose patients achieved a median overall survival (mOS) of 19.5 months, compared to the historical standard of care benchmark of approximately 14.6 months.
The trial is the first peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma.

The big picture

IN8bio's results mark a significant advancement in glioblastoma treatment, an area with minimal progress over the past two decades. The ability to engineer gamma-delta T cells resistant to chemotherapy and deliver them directly to the tumor site represents a novel approach that could redefine the treatment paradigm for this aggressive cancer. The publication in The Journal of Clinical Oncology lends credibility to these findings, potentially accelerating interest from investors and collaborators.

What we're watching

Clinical Development: Whether IN8bio can sustain these promising results in larger, more diverse patient populations.
Regulatory Pathway: The pace at which IN8bio advances DeltEx™ DRI through subsequent clinical trials and potential regulatory approvals.
Market Differentiation: How the unique combination of chemotherapy resistance and intracranial delivery positions DeltEx™ DRI against existing and emerging glioblastoma treatments.